Menu
Search
|

Menu

Close
X

Sierra Oncology Inc SRRA.OQ (NASDAQ Stock Exchange Global Market)

3.02 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 3.02
Open --
Volume --
3m Avg Volume 107,048
Today’s High --
Today’s Low --
52 Week High 4.09
52 Week Low 1.11
Shares Outstanding (mil) 52.27
Market Capitalization (mil) 100.36
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.458
FY16
-1.583
FY15
-115.639
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
0.52
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-38.70
14.43
Return on Equity (TTM)
vs sector
-38.70
16.13

EXECUTIVE LEADERSHIP

Donald Parfet
Independent Chairman of the Board, Since 2003
Salary: --
Bonus: --
Nicholas Glover
President, Chief Executive Officer, Director, Since 2014
Salary: $525,000.00
Bonus: --
Sukhi Jagpal
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
Barbara Klencke
Chief Development Officer, Since 2015
Salary: $420,000.00
Bonus: --
Mark Kowalski
Chief Medical Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2150-885 Georgia St W
VANCOUVER   BC   V6C 3E8

Phone: +1604.5586536

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.

SPONSORED STORIES